Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MHAA549A · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| MHAA4549A | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Tamiflu | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| MHAA549A | DRUG | IV dose |
| Placebo | DRUG | IV dose |
| oseltamivir [Tamiflu] | DRUG | Orally b.i.d, 5 days |
Inclusion Criteria: * In good health with no history of major medical conditions from medical history, physical examination and routine laboratory tests * Male subjects and women of child-bearing potential must use effective contraception as defined by protocol, starting at entry to quarantine and ...
MHAA549A is an investigational small molecule being developed by Roche Holding AG (RHHBY). It is currently in Phase 2 clinical development. The drug has been studied in healthy volunteers, specifically in an influenza challenge model, to evaluate its effects.
MHAA549A is being studied for use in healthy volunteers, particularly in an influenza challenge model. This means it is being tested to see how it affects healthy individuals who are exposed to the influenza virus in a controlled setting. The drug is still in clinical development and is not yet approved.
MHAA549A is being developed by Roche Holding AG, which trades under the ticker RHHBY. Roche is a multinational healthcare company that operates in pharmaceuticals and diagnostics. The drug is currently in Phase 2 clinical trials.
MHAA549A is in Phase 2 clinical development. It has completed one Phase 2 trial in healthy volunteers. The drug is investigational and has not been approved by regulatory authorities. It is still undergoing clinical testing to assess its safety and efficacy.
MHAA549A has one completed clinical trial, identified as NCT01980966. This was a Phase 2 study titled 'A Study of MHAA4549A in Healthy Volunteers in an Influenza Challenge Model.' The trial was conducted in the United Kingdom and enrolled 101 participants. It was a randomized, double-blind, placebo-controlled study.
Yes, MHAA549A is also known as MHAA4549A. The clinical trial NCT01980966, which studied the drug in healthy volunteers, uses the name MHAA4549A in its title. Both names refer to the same investigational drug being developed by Roche.